<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As a continuation to our previous work concerning antitumor <z:chebi fb="0" ids="36622">benzimidazoles</z:chebi>, we have synthesized series of new derivatives of 2-(1-<z:chebi fb="0" ids="22744">benzyl</z:chebi>-2-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1H-<z:chebi fb="0" ids="36622">benzimidazol</z:chebi>-5-ylimino)-3-(substituted)-thiazolidin-4-one (6a-e), 3-(2-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1H-<z:chebi fb="0" ids="36622">benzimidazol</z:chebi>-5-yl)-2-substituted-thiazolidin-4-one (9a-f) and we have studied their inhibitory activity against the Epstein-Barr virus-early antigen (EBV-EA) activation introduced by 12-O-tetradecanoylphorbol-13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Compound 6d was found to be significantly active and compounds 5a and 6e were also active </plain></SENT>
</text></document>